Items Tagged ‘Autologous Stem Cell Transplant’

May 7th, 2015

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma

By

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes in one region of the body and then spreads throughout the […]

View full entry

Tags: adcetris, Autologous Stem Cell Transplant, brentuximab vedotin, HL, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma, refractory, relapsed


November 12th, 2013

Treatment with Early Stem Cell Transplant Improves Outcomes in Aggressive NHL

By

Early autologous stem cell transplantation resulted in improved progression-free survival in patients with high-intermediate risk or high-risk disease who experienced a response to induction therapy, according to the results of a study published in the <i>New England Journal of Medicine</i>. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the […]

View full entry

Tags: Autologous Stem Cell Transplant, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Stem Cell Transplant


March 22nd, 2013

Zevalin Plus BEAM Chemotherapy Superior to BEAM Alone in Aggressive Lymphoma

By

Standard-dose Zevalin® (ibritumomab tiuxetan) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM therapy alone as a conditioning regimen for autologous stem cell transplantation (ASCT), according to the results of a study published in Cancer. High-dose chemotherapy plus autologous stem cell transplantation (ASCT) is standard therapy for refractory/relapsed aggressive lymphoma; however, […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Autologous Stem Cell Transplant, Lymphoma, News, Non-Hodgkin's Lymphoma, Stem Cell Transplant